Sentinel node in the era of neoadjuvant therapy and locally advanced XXXX .

@entity1 @entity0 @entity5 @entity809 @entity4269 @entity1600 @entity1442
The most important determinant of prognosis for @entity1 with @entity0 is the status of the axillary lymph nodes. @entity1600 ( @entity1600 ) has been performed for over a century to stage the @entity5 , achieve regional control, and perhaps improve survival. In accordance with tradition, @entity1600 has been performed on all @entity1 with the diagnosis of @entity0 . In the early 1990s, this dogma was challenged because of the significant morbidity associated with @entity1600 ( @entity809 , extremity @entity4269 ) and the fact that greater than 50% of all @entity0 are node negative. A less morbid but highly accurate staging procedure, lymphatic mapping and sentinel lymph node biopsy (SNB) was introduced. Currently, the de facto standard of care in @entity0 is to perform LM and SNB in @entity1 with small @entity5 and clinically negative axilla. While numerous methodological issues are being raised, the utility of LM and SNB identification continues to expand. In the current review we assess the application of this technique to locally advanced @entity0 (LABC) and neoadjuvant chemotherapy. What role does SNB play in locally @entity1442 ? Is LM and SNB accurate for @entity1 with @entity1442 ? What influence do axillary metastases have on further treatment? What is the role of SNB in the planning for neoadjuvant @entity1 ? The skillful management of @entity1 with @entity0 lies in the delicate balance between maximizing the efficacy of treatment and minimizing its morbidity and failure.
